Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lonza Forms JV With Shanghai Fosun To Tap Chinese Generics Market

This article was originally published in PharmAsia News

Executive Summary

Swiss firm Lonza Group AG, a global supplier of active pharmaceutical ingredients has announced a joint venture with Shanghai Fosun Pharmaceutical. The 50/50 JV will develop and launch a portfolio of generic products in China

You may also be interested in...



China's Largest Private Pharma Company Fosun Pharma Targets Biosimilar Market, With Sights On Becoming The Next Teva

SHANGHAI - China's largest private integrated healthcare company Shanghai Fosun Pharmaceutical Co. Ltd. will focus on gaining more market share in China with its branded generic business and branded traditional Chinese medicines, the company said during China's first ever Biotechnology Industry Organization conference held in Shanghai

China's Largest Private Pharma Company Fosun Pharma Targets Biosimilar Market, With Sights On Becoming The Next Teva

SHANGHAI - China's largest private integrated healthcare company Shanghai Fosun Pharmaceutical Co. Ltd. will focus on gaining more market share in China with its branded generic business and branded traditional Chinese medicines, the company said during China's first ever Biotechnology Industry Organization conference held in Shanghai

China's Largest Private Pharma Company Fosun Pharma Targets Biosimilar Market, With Sights On Becoming The Next Teva

Health care reform in the U.S. is a good opportunity for Fosun to gain a foothold in the U.S. market, company chair says at China's first-ever BIO conference.

Related Content

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel